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Abstract 26 
Inflammation is a key feature of preterm and term labour. Pro-inflammatory mediators are 27 
produced by gestation-associated tissues in response to pathogen-associated molecular 28 
patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Interleukin (IL)-4, 29 
IL-10 and IL-13 are anti-inflammatory cytokines with potential as anti-inflammatory 30 
therapies to prevent preterm birth. The objective of this study was to determine if IL-4 and 31 
IL-13 exert anti-inflammatory effects on lipopolysaccharide (LPS)-stimulated production of 32 
pro-inflammatory cytokines produced by human term gestation-associated tissues (placenta, 33 
choriodecidua and amnion). Both IL-4 and IL-13 reduced LPS-stimulated IL-1B and 34 
macrophage inflammatory protein (MIP)-1A; this effect diminished with delay to exposure to 35 
either cytokine. There was no effect on LPS-stimulated prostaglandin production. IL-4 36 
receptor alpha (IL-4RA) was expressed throughout the placenta, choriodecidua and amnion, 37 
and the inhibitory effects of IL-4 and IL-13 were IL-4RA-dependent. Combined IL-4 and IL-38 
13 did not enhance the anti-inflammatory potential of either cytokine; however, a 39 
combination of IL-4 and IL-10 had a greater anti-inflammatory effect than either cytokine 40 
alone. These findings demonstrate that human term gestation-associated tissues are 41 
responsive to the anti-inflammatory cytokines IL-4 and IL-13, which could down-regulate 42 
LPS induced cytokine production in these tissues. Anti-inflammatory cytokines might offer 43 
an adjunct to existing therapeutics to prevent adverse obstetric outcome. 44 
 45 
 46 
47 
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Introduction 48 
Preterm birth (PTB; < 37 weeks gestation) accounts for three-quarters of perinatal mortality 49 
and half of perinatal morbidity. Premature babies are prone to higher rates of complications 50 
of the gastrointestinal, renal and respiratory systems, and neurodevelopmental impairment 51 
and these problems persist into later life [1]. Both term and preterm labour, regardless of 52 
aetiology are considered inflammatory processes. Various inflammatory mediators ranging 53 
from cytokines and chemokines such as interleukin (IL)-1β IL-6, tumour necrosis factor 54 
alpha (TNFA), monocyte chemoattractant protein (MCP)-1, and IL-8 to prostaglandins, 55 
complement, and matrix metalloproteases (MMPs), contribute to cervical ripening, 56 
membrane rupture and/or myometrium contractility [2]. Targeting common inflammatory 57 
pathways might curtail the inflammatory cascade before myometrial contractions and cervical 58 
changes have occurred [3].  59 
 60 
The resolution of inflammation is essential for homeostasis. One mechanism by which this is 61 
achieved is the production of various anti-inflammatory molecules in response to an 62 
increased pro-inflammatory environment. A number of cytokines including IL-4, IL-10 and 63 
IL-13 are well recognised for their anti-inflammatory activity. Investigations into the use of 64 
anti-inflammatory cytokines to prevent PTB have focused primarily on IL-10. Animal studies 65 
have shown that IL-10 decreases lipopolysaccharide (LPS) induced placental nitric oxide, 66 
TNFA and apoptosis [4], and can prevent LPS mediated PTB in rats [5]. Ex vivo studies in 67 
humans have shown IL-10 can down-regulate LPS- and lipoteichoic acid (LTA)-induced 68 
cytokine and chemokine responses by the healthy term placenta [6], and inhibit IL-1B and 69 
prostaglandin E2 (PGE2) production and cyclooxygenase-2 (COX-2) expression in intact term 70 
fetal membranes [7]. However, the impact of other anti-inflammatory cytokines in this 71 
clinical setting is limited. 72 
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IL-4 and IL-13 are able to down-regulate the production of a variety of cytokines and 73 
chemokines, including IL-1β, TNFA, IL-8 and macrophage inflammatory protein (MIP)-1A 74 
[8-11]. They share functional characteristics through a common receptor component IL-4 75 
receptor alpha (IL-4RA) and share many signalling pathways including the Janus kinases 76 
(JAK) signalling pathway to activate signal transducer and activator of transcription 6 77 
(STAT6); the JAK/STAT pathway [12]. There are two types of IL-4 receptor – type I 78 
consisting of the common gamma chain (γc;  IL-2RG) and IL-4Rα; and type II consisting of 79 
IL-4RA and IL-13RA1. IL-4 first binds to IL-4RA and can signal via either receptor whereas 80 
IL-13 first binds to IL-13RA1 and only signals via the type II receptor [13]. Another receptor 81 
component, IL-13RA2, has been suggested to be a decoy receptor but this remains 82 
controversial [14]. Receptor activation by IL-4 and IL-13 ultimately leads to the activation of 83 
the transcription factors STAT6 and GATA3 (GATA binding protein 3) and the induction of 84 
IL-4/13 inducible genes to suppress Th1 and enhance Th2 immunity [12,15]. This anti-85 
inflammatory potential of both IL-4 and IL-13 has been explored therapeutically in a number 86 
of pathologies including renal cell carcinoma [16], Alzheimer’s disease [17], arthritis [18] and 87 
psoriasis [19] with variable results. 88 
 89 
As our knowledge of the biology of both IL-4 and IL-13 in gestation associated tissues is 90 
limited, we set out to examine both the activity of these cytokines and their classically 91 
described signalling pathways. We hypothesised that IL-4 and IL-13 down-regulate the 92 
inflammatory response in gestation-associated tissues as reported previously for IL-10. To 93 
examine this, an explant model of term gestation-associated tissues (placenta, choriodecidua 94 
and amnion) was utilised to determine the biological effects of IL-4 and IL-13 on the LPS 95 
induced inflammatory response by these tissues. 96 
 97 
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Materials and Methods 98 
Gestation associated tissues collection, preparation and stimulation 99 
Samples 100 
Healthy pregnant women (>37 weeks’ gestation; n=25) scheduled for elective caesarean 101 
section (ESC) were approached in the antenatal day assessment unit at Singleton Hospital, 102 
Swansea, during their pre-anaesthetic assessment. Informed written consent was obtained. 103 
Ethical approval for this study was given by the South West Wales Research Ethics 104 
Committee Wales and was conducted in accordance with the Declaration of Helsinki 105 
(2013) of the World Medical Association. Women undergoing ECS for fetal or maternal 106 
anomalies were not recruited therefore samples were typically from women scheduled for 107 
ECS because of breach presentation, cephalo-pelvic disproportion, or emergency section at 108 
previous delivery. Samples were transported to the laboratory and processed within 90 109 
minutes of delivery. Care was taken to minimise contamination by LPS/endotoxin when 110 
handling the placenta and the attached membranes. All procedures were performed in a class 111 
II tissue culture cabinet using disposable sterile consumables. Reagents used were determined 112 
by manufacturers to be endotoxin free.   113 
 114 
Explant Cultures 115 
Placenta. Placental explant cultures were prepared as described previously [20,21]. The 116 
decidua basalis overlaying the maternal side of the placenta was removed and 1 cm
3
 pieces of 117 
placental tissue cut from various sites across the placenta and placed into sterile calcium and 118 
magnesium free phosphate buffered saline (PBS; Thermo Fisher Scientific, UK). Tissue was 119 
washed repeatedly with PBS to remove contaminating blood and then minced into smaller 120 
pieces and washed further. Pieces of tissue (1 mm
3
 pieces to a total of 0.2 g) were transferred 121 
into the appropriate number of wells of a standard 12-well tissue culture plate (Greiner Bio-122 
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one, Germany) containing 1ml UltraCULTURE™ medium (Lonza, Switzerland), 123 
supplemented with 2 mM GlutaMAX™ (Thermo Fisher Scientific, UK) and 1% PSF 124 
(penicillin/streptomycin sulphate/fungizone®; Thermo Fisher Scientific, UK).  125 
 126 
Membranes. Membranes were detached from the placenta. Choriodecidua and amnion were 127 
separated from each other by blunt dissection and placed individually into PBS. Tissue was 128 
washed repeatedly with PBS to remove any contaminating blood. Explants were cut with an 129 
8mm biopsy punch (Steifel, Medisave, UK). For amnion, three pieces were transferred into 130 
each individual well of a 24-well tissue culture plate containing 0.5 ml of Advanced DMEM 131 
(Thermo Fisher Scientific, UK) supplemented with 2 mM GlutaMAX™, 2% FBS 132 
(HyClone™; Thermo Fisher Scientific, UK) and 1% PSF.  For choriodecidua, two pieces 133 
were transferred into each individual well of a 24-well tissue culture plate containing 0.5 ml 134 
Advanced RPMI supplemented with 2 mM GlutaMAX™, 2% FBS, 5mM 2-mercaptoethanol 135 
(2-ME; Thermo Fisher Scientific) and 1% PSF. 136 
 137 
Once prepared, explant cultures were stimulated with ultrapure LPS (10 ng/ml [20,21]; 138 
Invivogen, USA), and/or combinations of recombinant human IL-4, IL-10, and IL-13 (all 10 139 
ng/ml [22,23]; Miltenyi Biotec, UK); an unstimulated control was always included. 140 
Cytokines were added either pre- or post-LPS stimulation as detailed in the appropriate figure 141 
legends. All cultures were incubated for 24 hours. For inhibition/neutralisation experiments 142 
cultures were incubated with the following antibodies: anti-hIL-4RA IgG2a, Mouse IgG2a 143 
isotype (both 1 μg/ml; R&D Systems) for 30 minutes prior to the addition of cytokines/LPS.  144 
 145 
RNA Extraction from Gestation-Associated Tissue Samples 146 
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Biopsies of tissue were preserved in TRI reagent (Sigma-Aldrich, UK) at -20°C. DNA-free 147 
RNA was prepared from homogenised tissue (FastPrep FP120A Homogeniser; Qbiogene, 148 
The Netherlands) following the TRIzol method of extraction and DNA-free DNase kit 149 
(Ambion®, Thermo Fisher Scientific, UK) as per manufacturer’s instructions. Purity and 150 
concentration of RNA were measured (NanoDrop 3300 flurospectrometer; NanoDrop 151 
Technologies, USA).  152 
 153 
Polymerase Chain Reaction (PCR) 154 
Reverse transcription was performed using the RETROscript kit (Ambion®, Thermo Fisher 155 
Scientific, UK) as per manufacturer’s instructions. Polymerase chain reaction was performed 156 
using the Platinum® Taq DNA Polymerase kit and dNTP Mix (both Thermo Fisher 157 
Scientific, UK). All primers were synthesised by Thermo Fisher Scientific, using sequences 158 
obtained using primer BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). UBE2D2 159 
housekeeping primers were based on previously published sequences [24]. Primer sequences 160 
and specific conditions to each PCR are listed in Table 1.   161 
 162 
Cytokine and prostaglandin production 163 
IL-1β, MIP-1α and PGE2 in the tissue free supernatants of explant cultures collected after 24 164 
h were measured using commercially available immunoassay kits (IL-1β and MIP-1α, 165 
DuoSet; PGE2, Parameter; all R&D Systems) as per manufacturer’s instructions.  166 
 167 
Immunohistochemistry 168 
Immunohistochemical staining for IL-4RA was performed on formalin fixed, paraffin 169 
embedded sections (4 µm) of placenta and fetal membranes using the Ventana ULTRA 170 
automated staining instrument with the OptiView DAB detection kit. Antigen retrieval used 171 
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cell conditioning 1 (CC1) for 16 mins at 98°C. Mouse monoclonal anti-IL-4RA (3 µg/ml; 172 
R&D Systems, USA) primary antibody was incubated at room temperature for 24 minutes. 173 
Control slides where primary antibody was replaced with mouse IgG2a isotype control 174 
(eBioscience) at the same concentration were also included. Tonsil was used as a positive 175 
control tissue. 176 
 177 
Statistical analysis 178 
All experiments were performed a minimum of three times. Statistical analysis was 179 
performed using GraphPad Prism (Version 6, GraphPad Software Inc, USA). Agonist 180 
mediated cytokine production by non-laboured tissues was evaluated by one-way ANOVA 181 
with Tukey post hoc test for multiple comparisons. Difference between cytokine (IL-1B 182 
versus MIP-1A)/tissue (placenta versus choriodecidua versus amnion) response was 183 
evaluated by two-way ANOVA with Tukey post hoc test for multiple comparisons. A p-value 184 
of ≤ 0.05 was considered significant. 185 
 186 
187 
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Results 188 
Pre-treatment with IL-4 or IL-13 inhibits LPS induced cytokine output of placenta, 189 
choriodecidua and amnion  190 
LPS treated gestational tissues produce a robust inflammatory response measurable as 191 
increased levels of various cytokines and chemokines [20,21], therefore LPS exposed tissues 192 
were used as a relevant inflammatory model. Tissue explants were pre-incubated with IL-4 or 193 
IL-13 at a standard concentration of 10 ng/ml [22] for 90 minutes prior to the addition of LPS 194 
for 24 h. For all three tissues, a significant decrease in both LPS-stimulated IL-1B and MIP-195 
1A was observed in the presence of IL-4 or IL-13 (Figure 1). A similar anti-inflammatory 196 
effect of IL-4 or IL-13 pre-treatment when LPS was substituted for Pam3CSK4 (TLR2/1), 197 
FSL-1 (TLR2/6) and Tri-DAP (NOD1) (Supplementary Figure 1). While not significantly 198 
different IL-4 generally has a greater anti-inflammatory effect than IL-13. Despite using the 199 
same concentration for both cytokines, a molar to molar comparison of IL-4 (6.62 nM) versus 200 
IL-13 (7.94 nM) would suggest that IL-4 is more effective. A trend for a greater percentage 201 
reduction was seen for IL-1B than MIP-1A in all tissues, however with was only significant 202 
in the amnion but for both IL-4 (p < 0.05) and IL-13 (p < 0.05). Additionally, the greatest 203 
percentage reduction in cytokine outputs by IL-4 or IL-13 pre-treatment was in the placenta 204 
with the least in the amnion; this is only significant for the reduction of MIP-1A following 205 
IL-13 pre-treatment (placenta versus amnion; p < 0.001).   206 
 207 
The effect of IL-4 or IL-13 on gestation associated tissues is IL-4RA dependent manner 208 
Since both IL-4 and IL-13 pre-treatment has a biological effect on LPS induced cytokine 209 
production, we investigated IL-4/IL-13 signalling components in gestation-associated tissues. 210 
Expression of receptor and signalling components of the IL-4/IL-13 signalling pathways was 211 
investigated at the RNA level using conventional PCR. Transcripts for IL-4 receptor alpha 212 
10 
 
(IL-4RA), the common gamma chain (γc, IL-2RG), IL-13 receptor alpha 1 (IL-13RA1), and 213 
STAT6 were expressed in all 5 examples of placenta, choriodecidua and amnion. IL-13RA2 214 
was expressed by all 5 examples of placenta and choriodecidua but showed varied expression 215 
in the amnion including 2 samples where it was not expressed (Figure 2A).  216 
 217 
Immunohistochemistry was used to determine the localisation of IL-4RA, a common receptor 218 
subunit utilised by both IL-4 and IL-13 [13]. In the placenta, expression was localised to the 219 
trophoblast and cells within the stroma, while in the fetal membranes expression was 220 
localised to the amnion epithelial cells, chorionic trophoblast and various cells within the 221 
decidua (Figure 2B). Expression of IL-4RA was consistent in all seven examples of placenta 222 
and membranes stained. There was negligible background in the negative controls for either 223 
the placenta or fetal membranes (Figure 2B). Tonsil was used as a positive control. 224 
 225 
To confirm the functional activity of IL-4RA within gestational tissues, IL-4RA was 226 
inhibited with a neutralising antibody. In the presence of this antibody the effect of both IL-4 227 
and IL-13 on LPS-induced IL-1B and MIP-1A was abrogated (Figure 3A-F), however, this 228 
was not significant (p=0.1) for IL-13 in the amnion in relation to MIP-1A. This confirms the 229 
role of IL-4RA in IL-4 and IL-13 signalling in the placenta, choriodecidua and amnion.  230 
 231 
IL-4 and IL-13 abrogate LPS induced cytokine production by gestation associated tissues in 232 
a therapeutic ex vivo model 233 
While pre-treatment with either IL-4 or IL-13 is able to reduce LPS induced cytokine levels, 234 
this does not mimic the typical clinical setting wherein the inflammatory insult would likely 235 
precede therapeutic intervention. Therefore, the ability of both IL-4 and IL-13 to modulate 236 
cytokine production post-LPS exposure was examined. To investigate this, tissue explants 237 
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were treated with LPS and IL-4 or IL-13 added either 90 minutes prior to LPS (as in Figure 238 
3), concurrently, or at arbitrary time points of 90 or 240 minutes post-LPS treatment allowing 239 
for the development of an inflammatory environment to mimic a clinical setting. IL-4 and IL-240 
13 retain inhibitory effects when added after LPS; however, the statistical significance of this 241 
response is diminished with delay to adding IL-4 or IL-13 (Figure 4). This is most apparent at 242 
240-minute post treatment where a significant reduction in cytokine response no longer 243 
occurs, with the exception of IL-4 treated placenta. Furthermore, in IL-13 treated amnion 244 
there was no significant effect with either concurrent or post-LPS treatment with the 245 
cytokine, highlighting the reduced potential of IL-13 in this setting. 246 
 247 
A combination of IL-4 and IL-13 does not enhance the anti-inflammatory properties of 248 
either cytokine  249 
Since the effect of both IL-4 and IL-13 was diminished following exposure post-LPS 250 
treatment, the effect of co-treatment with both cytokines was examined. Tissues were treated 251 
with either IL-4 alone, IL-13 alone or IL-4 and IL-13 in combination at 90 and 240 minutes 252 
post-LPS exposure. The response with IL-4 and IL-13 co-treatment did not differ 253 
significantly from the response to individual treatment with IL-4 or IL-13 (Figure 5). 254 
 255 
Impact of IL-4/IL-13 on prostaglandin production by gestation-associated tissues 256 
In addition to many pro-inflammatory cytokines, prostaglandins have a key role in facilitating 257 
the physiological processes of labour. Therefore, the effect of IL-4 and IL-13 alone or in 258 
combination on PGE2 levels was considered. IL-4 and IL-13 had no effect on PGE2 levels 259 
from LPS-treated placental and amnion explant cultures when added 90 or 240 minutes after 260 
LPS exposure (Figure 6). In the choriodecidua, both IL-4 and IL-13 reduced the levels of 261 
LPS-induced PGE2, with a combination of both cytokines resulting in a significant reduction 262 
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when added 90 minutes after LPS treatment. This effect was lost by 240 minutes post-LPS 263 
exposure.  264 
 265 
IL-10 enhances the anti-inflammatory properties of IL-4  266 
Since IL-10 has been shown previously to inhibit cytokine production in the term placenta 267 
and fetal membranes [6], the possibility that co-treatment with IL-10 could enhance the 268 
inhibitory effect of IL-4 administered post-LPS stimulation was considered. In all three 269 
tissues, co-treatment with IL-4 and IL-10 at 90 minutes’ post LPS exposure resulted in an 270 
enhanced decrease in cytokine production compared to either cytokine alone, however this 271 
was only significant in the choriodecidua for MIP-1A (IL-4+IL-10 versus IL-4 alone; Figure 272 
7). An enhanced decrease in cytokine production is still observed at 240 minutes post-LPS 273 
exposure with combined IL-4/IL-10. This was most notable in the choriodecidua and amnion 274 
where significant reduction with co-treatment was observed in relation to IL-4/IL-10 versus 275 
IL-4 (MIP-1A) and IL-4/IL-10 versus IL-10 (IL-1B) (Figure 7).  276 
277 
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Discussion 278 
Cytokine production at the maternal-fetal interface is a part of normal pregnancy. Changes in 279 
cytokine production occur with term and preterm labour [2]; whether such changes precede 280 
labour and might serve as targets for therapeutic intervention in adverse obstetric outcomes 281 
remains to be determined. Maternal and fetal indications, e.g. preeclampsia, account for up to 282 
35% of PTB but the pathophysiological mechanisms underlying the bulk of PTB are largely 283 
unknown. Evidence supports inflammatory processes: heterogeneous pro-inflammatory 284 
profiles reflecting different underlying causes of PTB, including infection. Targeting 285 
common inflammatory pathways might curtail the inflammatory cascade before myometrial 286 
contractions and cervical changes occur to prevent preterm delivery. Anti-inflammatory 287 
cytokines such as IL-4 and IL-13 but also IL-10 might offer this therapeutic potential [25]. As 288 
noted above the effects of IL-10 upon gestation-associated tissues are relatively well studied 289 
[4-6], therefore the ability of IL-4 and IL-13 to dampen the inflammatory response by 290 
gestation-associated tissues (placenta, choriodecidua and amnion) was examined.  291 
 292 
Using LPS as a known inducer of cytokine production by gestational tissues [20,21] and a 293 
standard initiator of infection induced preterm labour in animal models [5], we showed that 294 
both IL-4 and IL-13 can down-modulate stimulated cytokine (IL-1B) and chemokine (MIP-295 
1A) responses by all three tissue types studied. These anti-inflammatory effects of IL-4 and 296 
IL-13 were IL-4RA dependent and expression of IL-4Rα was observed on multiple cell types 297 
throughout the placenta, choriodecidua and amnion. IL-4 and IL-13 also utilise several 298 
signalling molecule and transcription factors, including STAT6, GATA3, PI3K, MAP kinases 299 
and AMPK [26,27], likely contributing to the anti-inflammatory environment generated by 300 
these cytokines. For example, activation of AMPK in fetal membranes treated with TLR 301 
ligands is associated with a reduced pro-inflammatory output compared to TLR activation 302 
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without an AMPK activator [28] which might relate to the down-regulation of TLR 303 
expression or function [29]. IL-4 and IL-13 may also target common signalling components 304 
of pattern recognition receptors. Similarly to the effect on LPS, pre-treatment with IL-4 and 305 
IL-13 was shown to attenuate cytokine production by several other bacterial agonists, namely 306 
Pam3CSK4 (TLR2/1), FSL-1 (TLR2/6) and Tri-DAP (NOD1).  While this effect has only 307 
been examined in the relation to bacterial agonists, both viral infection and sterile 308 
inflammation mediated by DAMPs may cause PTB [2]. However regardless of the 309 
inflammatory trigger innate signalling pathways triggered by bacteria, virus or DAMPs all 310 
utilise common signalling components such as MAP kinases and the transcription factor AP-311 
1 which can be negatively impacted by IL-4 and IL-13 [2,30,31]. 312 
 313 
 314 
IL-4 and IL-13 tended to cause a greater percentage reduction in LPS-induced IL-1B than 315 
MIP-1A although this was only significant in the amnion. Since IL-4 and IL-13 down-316 
regulate both IL-1B and MIP-1A gene expression in other settings [10,11], this difference 317 
might relate to greater non-transcriptional regulation of the inflammasome by IL-4 [32]. 318 
Impaired inflammasome assembly and subsequent activation would limit the maturation of 319 
IL-1B from its pro-form to the mature secreted form. The inhibition of IL-1B by IL-13 and 320 
other anti-inflammatory cytokines likely occurs by a similar mechanism. 321 
 322 
Although not significant, IL-4 in general had a greater inhibitory effect compared to IL-13 on 323 
LPS-induced IL-1B and MIP-1A production, with the exception of IL-1B in the 324 
choriodecidua and MIP-1α in the amnion. Any differential effects of these cytokines might 325 
relate to relative expression of signalling components other than IL-4RA. While PCR 326 
analysis of the placenta, choriodecidua and amnion revealed transcripts of all components of 327 
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the IL-4/IL-13 signalling pathway (IL-4RA, IL-2RG, IL-13RA1, IL-13RA2 and STAT6) a 328 
quantitative method was not used so other than the obvious variation in IL-13RA2 in the 329 
amnion it is not possible to provide any detail on relative levels of these signalling 330 
components in each tissue. The varied expression of IL-13RA2 in amnion could impact the 331 
effectiveness of IL-4 and IL-13 in this tissue. While classically described as a decoy receptor 332 
due to its high affinity binding, fast association rate and slow dissociation rate for IL-13, IL-333 
13RA2 might also have some signalling capabilities including the activation of the 334 
transcription factor AP-1 in macrophages [33]. IL-13RA2 can also affect IL-4 335 
responsiveness, due to interaction of its cytoplasmic tail with IL-4RA preventing the 336 
association of JAK1 and the subsequent downstream signalling [34].  337 
 338 
While both IL-4 and IL-13 could down regulate LPS-induced pro-inflammatory cytokine 339 
production when tissues were pre-treated with these cytokines, in a clinical setting any 340 
intervention would likely occur after the inflammatory insult. To explore if IL-4 and IL-13 341 
would be effective post insult as would occur clinically, the effect of IL-4 and IL-13 on 342 
gestation-associated tissues post-LPS exposure at arbitrary time points was determined. The 343 
anti-inflammatory effect of these cytokines was diminished with delayed treatment post-LPS 344 
exposure. When added following 240-minute exposure of the tissues to LPS the anti-345 
inflammatory effect of both IL-4 and IL-13 was negligible.  This might relate to the induction 346 
of SOCS1, a negative regulator of JAK/STAT signalling pathways by LPS in a TLR4 347 
dependent manner [12,35]. While a standard concertation of IL-4 and IL-13 was utilised here, 348 
it is unknown if any dose dependent effects would have been observed with higher 349 
concentrations potentially yielding a greater anti-inflammatory effect post-exposure to LPS. 350 
Examining any potential dose-dependent effects might aid in our understanding of how these 351 
cytokines could be used therapeutically. However, a previous study in peripheral blood 352 
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mononuclear cells noted a maximal suppressive effect of IL-4 on LPS-induced IL-1B at a 353 
concentration of 10 ng/ml with no enhanced effect at 100 ng/ml [36]. It should also be noted 354 
that a reverse dose response for IL-10 has been observed in placental explants, where 10 355 
ng/ml had a greater effect on macrophage migration inhibitory factor (MIF) than 25 ng/ml in 356 
human placental explants, with this effect greater in first trimester explants versus third [37]. 357 
 358 
Co-treatment with both IL-4 and IL-13 did not enhance the anti-inflammatory effects of 359 
either cytokine; this is likely due to the utilisation of similar signalling components. 360 
Furthermore, combined IL-4, IL-13 or IL-4 and IL-13 had little impact on the production of 361 
PGE2 by gestation associated tissues other than for the choriodecidua 90 minutes post-LPS 362 
exposure. This suggests that while these anti-inflammatory cytokines can modulate the 363 
production of pro-inflammatory cytokines by gestational tissues, downstream molecules are 364 
not affected. To date treatment strategies for PTB have focused on inhibiting myometrial 365 
contractions utilising an array of compounds including cyclooxygenase inhibitors, oxytocin 366 
antagonists, magnesium sulphate and B-mimetics [38]. Each of these treatment strategies 367 
targets late stage events in the labour process and not the upstream causes of an inflammatory 368 
cascade. Given IL-4 and IL-13 had negligible effects on PGE2, combination therapy with an 369 
anti-inflammatory approach as described here with anti-contraction medications would likely 370 
be needed [39]. 371 
 372 
As IL-10 has been described as an effective anti-inflammatory in a similar experimental 373 
setting we investigated the effects of combination IL-4 and IL-10. A combination of IL-4 and 374 
IL-10 has been suggested as a treatment for preeclampsia with promise shown in an animal 375 
model [40].  The combination of IL-4 and IL-10 had a greater effect in reducing the levels of 376 
LPS-induced cytokine production at both 90 minutes and 240 minutes post-LPS stimulation 377 
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than either cytokine alone, with the greatest effect in the choriodecidua, but this was not 378 
always significant. This enhanced effect likely results from the activation of both shared and 379 
specific downstream targets of IL-4 and IL-10. For example, both IL-4 and IL-10 enhance the 380 
expression of IL-1 receptor antagonist (IL-1RA) [41], a potent anti-inflammatory cytokine 381 
involved in the inhibition of IL-1A and IL-1B [42]. In contrast, the micro RNA miR-146b, 382 
which is upregulated by IL-10 but not IL-4 or IL-13 in human monocytes, can inhibit TLR4 383 
dependent signalling [43]. Therefore, combined IL-4 and IL-10 offer a promising therapeutic 384 
approach to curtailing the inflammatory cascade at the maternal-fetal interface.  385 
 386 
IL-4, IL-10 and IL-13 have all been reported to be produced by trophoblast, decidua and 387 
amnion and to have homeostatic roles in pregnancy [44]. While advocating a role for these 388 
cytokines as anti-inflammatory therapeutics to prevent PTB it must be noted that both IL-4  389 
[45] and IL-10 [46] are increased in amniotic fluid from women who delivered preterm both 390 
with and without evidence of intra-amniotic infection. This likely represents a compensatory 391 
mechanism that has failed and our proposed approach might augment the body’s own 392 
protective mechanisms. Furthermore, understanding how these cytokines might function in 393 
preterm tissues versus term tissues, in relation to both the relative expression of signalling 394 
components in addition to their functional activity is required. The therapeutic potential of 395 
IL-4 and IL-10 in humans in other disease settings has yielded variable and often 396 
disappointing results [16,25] highlighting that the therapeutic use of highly pleiotropic native 397 
cytokines is hampered by side effects related to delivery, degradation, toxicology and off-398 
target effects. The identification of peptides that deliver only the desired biological effect 399 
might overcome this. A 16 amino acid peptide (Ph8) based on alpha-helix C of IL-4 has been 400 
reported and had anti-inflammatory effects but no effect on the Th1/Th2 cytokine profile 401 
[47]. Clearly, more work is required to better understand the action of anti-inflammatory 402 
18 
 
cytokines at the maternal-fetal interface in both physiological and pathological settings and to 403 
devise strategies to harness their therapeutic potential.   404 
 405 
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 552 
Table Legends 553 
Table 1. Specifications for PCR. 554 
Primer sequences for IL-4/IL-14 signalling components and optimum conditions for each pari 555 
of primers. 556 
 557 
Figure Legends 558 
 559 
Figure 1.  Effect of IL-4 and IL-13 on LPS-induced cytokine production by term non-560 
laboured gestation associated tissues. 561 
Cytokine levels (IL-1B & MIP-1A) from explants of (A-B) placenta (C-D) choriodecidua and 562 
(E-F) amnion in response to treatment with IL-4 or IL-13 (both 10 ng/ml) 90 minutes prior to 563 
treatment with LPS (10 ng/ml). Data shown as percentage of response to LPS alone (n=6); 564 
error bars represent SEM. Statistically significant differences compared to control treatment 565 
are shown: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 **** p ≤ 0.0001. 566 
 567 
Figure 2. Expression of the IL-4/13 signalling pathway components by term non-laboured 568 
gestation-associated tissues. 569 
(A) PCR for each of the receptor chains involved in IL-4 and IL-13 signalling as well as the 570 
main transcription factor STAT6. Three representative samples of 5 are shown. Human spleen 571 
22 
 
(S) was used as a positive control and UBE2D2 was used as a housekeeping gene. L = 100 572 
base pair ladder and the negative control (-ve) was with water replacing cDNA in the reaction 573 
mix. (B) Sections of formalin-fixed paraffin-embedded placenta and fetal membranes were 574 
stained with an anti-human IL-4RA antibody; samples from 7 individuals were examined; a 575 
representative is shown. Human tonsil was used as the positive control. Original 576 
magnification x 10. T – Trophoblast, S – Stroma, BV – Blood Vessel, Am – Amnion, Cd – 577 
Chorion, Dec – Decidua, GC – Germinal Centre, TC – Tonsilar Crypt, E – Epithelium. 578 
 579 
 580 
Figure 3.  Anti-inflammatory effects of IL-4 and IL-13 in the placenta, choriodecidua 581 
and amnion are IL-4RA-dependent.  582 
Cytokine levels (IL-1B & MIP-1A) from explants of (A-B) placenta, (C-D) choriodecidua 583 
and (E-F) amnion in response to LPS (10 ng/ml) pre-treated for 90 minutes with IL-4 or IL-584 
13 (both 10 ng/ml) in the presence or absence of mouse IgG2a anti-human IL-4RA antibody 585 
or mouse IgG2a isotype. Data are shown as % of LPS alone (n = 3); error bars represent 586 
SEM. Statistically significant differences compared to LPS + IL-4/13 treatments are shown: * 587 
p ≤ 0.05, ** p ≤ 0.01.  588 
 589 
Figure 4. Effect of IL-4 and IL-13 treatment over time on LPS-induced cytokine 590 
production by term non-laboured gestation-associated tissues. 591 
Cytokine levels (IL-1B & MIP-1A) from explants of (A) placenta (B) choriodecidua and (C) 592 
amnion in response to LPS (10 ng/ml) in the presence of IL-4 or IL-13 (10 ng/ml) added 90 593 
minutes prior to LPS (T-90), at the same time as LPS (T0), or 90 minutes (T+90) or 4 hours 594 
(T+240) after LPS (n=3). Data are shown as percentage of response to LPS alone; error bars 595 
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represent SEM. Statistically significant differences compared to LPS treatment are shown: * 596 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 597 
 598 
Figure 5. Combined effect of IL-4 and IL-13 treatment on LPS-induced cytokine 599 
production by term non-laboured gestation-associated tissues. 600 
Cytokine levels (IL-1B & MIP-1A) from explants of (A) placenta (B) choriodecidua and (C) 601 
amnion in response to LPS (10 ng/ml) in the presence of IL-4, IL-13 or IL-4 + IL-13 (all 10 602 
ng/ml) added 90 minutes (T+90) or 4 hours (T+240) after LPS (n=3). Data are shown as 603 
percentage of response to LPS alone; error bars represent SEM. Statistically significant 604 
differences compared to LPS treatment are shown: * p ≤ 0.05, ** p ≤ 0.01.  605 
 606 
Figure 6. Combined effect of IL-4 and IL-13 treatment on LPS-induced PGE2 607 
production by term non-laboured gestation-associated tissues. 608 
PGE2 from explants of (A) placenta (B) choriodecidua and (C) amnion in response to LPS 609 
(10 ng/ml) in the presence of IL-4, IL-13 or IL-4 + IL-13 (all 10 ng/ml) added 90 minutes 610 
(T+90) or 4 hours (T+240) after LPS (n=3). Data are shown as percentage of response to LPS 611 
alone; error bars represent SEM. Statistically significant differences compared to LPS 612 
treatment are shown: * p ≤ 0.05.  613 
 614 
Figure 7. Combined effect of IL-4 and IL-10 treatment on LPS-induced cytokine 615 
production by term non-laboured gestation-associated tissues. 616 
Cytokine levels (IL-1B & MIP-1A) from explants of (A) placenta (B) choriodecidua and (C) 617 
amnion in response to LPS (10 ng/ml) in the presence of IL-4, IL-10 or IL-4 + IL-10 (all 10 618 
ng/ml) added 90 minutes (T+90) or 4 hours (T+240) after LPS (n=3). Data are shown as 619 
24 
 
percentage of response to LPS alone; error bars represent SEM. Statistically significant 620 
differences compared to LPS treatment are shown: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.  621 
 622 
 623 
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Table 1 624 
Gene Primer Mg
2+  
Conc (nM) Anneling Temp (°C) 
Fragment Size 
(Bp) 
Accession 
Number 
IL-4RA 
F 5' GACCTGGAGCAACCCGTATC 
2.5 70 335 NM_000418 
R 5' CATAGCACAACAGGCAGACG 
IL-2RG 
F 5' ACGGGAACCCAGGAGACAGG 
2 70 275 NM_000206 
R 5' AGCGGCTCCGAACACGAAAC 
IL-13RA1 
F 5' GAGCTGACCAAAGTGAAGGA 
3 69 518 NM_001560  
R 5' ATTGCACCTGCGACGATGACTG 
IL-13RA2 
F 5' GGCATAGGTGATCTTCTTGA 
2 60 559 NM_000640  
R 5' GCCAGAAACGATGCAAAGTTT 
STAT6 
F 5' AGAGGGGTTGCCGAGGTGA 
4 70 755 NM_001178078 
R 5' TGTCCACCAGGCTTTCACAC 
UBE2D2 
F 5' GATCACAGTGGTCTCCAGCA 
3 65 156 
Popov et al 2010 
(ref 33) R 5' TCCATTCCCGAGCTATTCTG 
26 
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Figure 2A 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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